Knowledge Beyond
Research & Development Division of Stratus
Biomarker
Services
Creation of models to detect drug or disease state EEG biomarkers for pre-clinical and clinical pharmaceutical studies.
EEGenix Research
Database
More than 50,000 anonymized video EEG reports with linked anonymized EEG clips. Available for academic studies through a web-based search platform.
Deep Learning
Tools
Artificial Intelligence applications for all aspects of video EEG Monitoring.
Research
Partnerships
Contact us to discuss your academic, pharmaceutical, or medical device needs.
Developing the Next Generation of Neurophysiology Studies
MERLN is focused on research, development and deployment of innovative services and technologies to improve the quality and data of neurophysiology studies. Current projects under development include individualized EEG recording systems, machine learning, and artificial intelligence (AI) interpretation of EEG.
MERLN, LLC. is the research and development division of Stratus d/b/a Alliance Family of Companies.
EEGenix Database
MERLN has created a natural language processing (NLP) database to allow rapid review of our dataset of more than 50,000 anonymized Video EEG reports and attached pruned EEG data for academic and commercial research purposes.
Deep-Learning Biomarker Pipeline
MERLN has created a combination of feature extraction and deep learning software in a rapidly reconfigurable pipeline. The software is capable of detecting subtle differences between EEGs obtained in different clinical states for the creation of potential biomarkers of drugs and disease states. This is offered as a service to pharmaceutical companies, or anyone interested in identifying biomarkers through the use of EEG.
Research Collaboration
MERLN is committed to collaboration with academic, pharmaceutical, or medical device projects. Contact us to set up a time to discuss your opportunity.
Meet Jeremy Slater, M.D.
Dr. Slater has worked in the field of epilepsy for more than 27 years. He served as the Director of the Texas Comprehensive Epilepsy Program from 2004 to 2018, growing the center from a single neurologist and neurosurgeon to one of the largest epilepsy surgery programs in the country. He has served as an investigator for numerous clinical trials of novel anticonvulsants and medical devices. His early research work focused on the potential for applying techniques of the developing field of artificial neural networks to classification problems in clinical neurophysiology. These studies demonstrated the ability of such networks to distinguish disease states with a level of discrimination higher than achieved through statistical or human visual analysis. While the architectures have evolved and now such analyses are commonplace, these were the first such studies of their kind. His more recent research has focused on changes to brain electrical activity related to drowsiness. In 2018, Dr. Slater joined the Stratus as Chief Medical Officer.